Latest & greatest articles for side effects

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on side effects or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on side effects and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for side effects

81. Dose response relationships for efficacy and side effects for the major classes of blood pressure lowering drugs: a systematic review and meta-analysis protocol

Dose response relationships for efficacy and side effects for the major classes of blood pressure lowering drugs: a systematic review and meta-analysis protocol Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr (...) Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures Timing and effect measures Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Context and rationale Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Example: Screening will be performed in two phases, namely initial

2015 PROSPERO

82. Effect of dexmedetomidine in preventing postoperative side effects for laparoscopic surgery: a meta-analysis of randomized controlled trials

Effect of dexmedetomidine in preventing postoperative side effects for laparoscopic surgery: a meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne (...) ") for correspondence: Organisation web address: Timing and effect measures Timing and effect measures Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Context and rationale Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Example: Screening will be performed in two phases, namely initial screening based on title

2015 PROSPERO

83. Acupoint stimulation for alleviating side effects of chemotherapy or radiotherapy in patients with cancer: a systematic review

Acupoint stimulation for alleviating side effects of chemotherapy or radiotherapy in patients with cancer: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne (...) ") for correspondence: Organisation web address: Timing and effect measures Timing and effect measures Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Context and rationale Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Example: Screening will be performed in two phases, namely initial screening based on title

2015 PROSPERO

84. Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone and olanzapine dose reduction

Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone and olanzapine dose reduction Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone and olanzapine dose reduction | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie (...) settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Improving symptoms and side effects

2015 Evidence-Based Mental Health

85. A review of questionnaires used in clinical practice assessing subjective beliefs of side effects of psychotropic medications

A review of questionnaires used in clinical practice assessing subjective beliefs of side effects of psychotropic medications Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne (...) ") for correspondence: Organisation web address: Timing and effect measures Timing and effect measures Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Context and rationale Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Example: Screening will be performed in two phases, namely initial screening based on title

2015 PROSPERO

86. Effects of vertical and side-alternating vibration training on fall risk factors and bone turnover in older people at risk of falls Full Text available with Trip Pro

Effects of vertical and side-alternating vibration training on fall risk factors and bone turnover in older people at risk of falls whole-body vibration training may improve neuromuscular function, falls risk and bone density, but previous studies have had conflicting findings.this study aimed to evaluate the influence of vertical vibration (VV) and side-alternating vibration (SV) on musculoskeletal health in older people at risk of falls.single-blind, randomised, controlled trial comparing

2014 EvidenceUpdates Controlled trial quality: uncertain

87. [Lactobacillus rhamnosus GG supplementation to reduce side-effects of anti-Helicobacter pylori treatment]. (Abstract)

[Lactobacillus rhamnosus GG supplementation to reduce side-effects of anti-Helicobacter pylori treatment]. Helicobacter pylori (Hp) eradication fails in about 10% of patients because of the occurrence of resistance to antibiotics and side-effects. During anti H.pylori therapy, probiotics have been used to reduce the incidence of side-effects.To determine whether adding the probiotic Lactobacillus rhamhousus GG to an anti-H. pylori regimen could help to prevent or minimize the gastrointestinal (...) side-effect burden.66 subjects screening positive for H. pylori infection (male/female: 45/21, mean age 56,6 DS ± 16,7 year ), 59 subjects receiving 7 days of Omeprazole 20 mg b.i.d, Amoxicillin 1000 mg b.i.d and Clarithromycin 500 mg b.i.d were randomly assigned to Lactobacillus rhamnosus GG (6 x 9 ufc b.i.d ) (n = 29) or placebo (n = 30). Patients completed questionnaires after the treatment to determine the type and 10 severity of side-effects.Side effects occurred mainly during the eradication

2014 Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru Controlled trial quality: uncertain

88. [Lactobacillus rhamnosus GG supplementation to reduce side-effects of anti-Helicobacter pylori treatment]. (Abstract)

[Lactobacillus rhamnosus GG supplementation to reduce side-effects of anti-Helicobacter pylori treatment]. Helicobacter pylori (Hp) eradication fails in about 10% of patients because of the occurrence of resistance to antibiotics and side-effects. During anti H.pylori therapy, probiotics have been used to reduce the incidence of side-effects.To determine whether adding the probiotic Lactobacillus rhamhousus GG to an anti-H. pylori regimen could help to prevent or minimize the gastrointestinal (...) side-effect burden.66 subjects screening positive for H. pylori infection (male/female: 45/21, mean age 56,6 DS ± 16,7 year ), 59 subjects receiving 7 days of Omeprazole 20 mg b.i.d, Amoxicillin 1000 mg b.i.d and Clarithromycin 500 mg b.i.d were randomly assigned to Lactobacillus rhamnosus GG (6 x 9 ufc b.i.d ) (n = 29) or placebo (n = 30). Patients completed questionnaires after the treatment to determine the type and 10 severity of side-effects.Side effects occurred mainly during the eradication

2014 Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru Controlled trial quality: uncertain

89. Statins may have fewer side effects than is claimed, meta-analysis finds. (Abstract)

Statins may have fewer side effects than is claimed, meta-analysis finds. 24633266 2015 04 06 2018 12 02 1756-1833 348 2014 Mar 14 BMJ (Clinical research ed.) BMJ Statins may have fewer side effects than is claimed, meta-analysis finds. g2151 10.1136/bmj.g2151 bmj.g2151 Wise Jacqui J London. eng News Comment 2014 03 14 England BMJ 8900488 0959-8138 0 Hydroxymethylglutaryl-CoA Reductase Inhibitors AIM IM Eur J Prev Cardiol. 2014 Apr;21(4):464-74 24623264 Humans Hydroxymethylglutaryl-CoA (...) Reductase Inhibitors adverse effects 2014 3 18 6 0 2014 3 19 6 0 2015 4 7 6 0 epublish 24633266 10.1136/bmj.g2151

2014 BMJ

90. This asthma treatment has a lasting side effect in children

This asthma treatment has a lasting side effect in children This asthma treatment has a lasting side effect in children Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics This asthma treatment has a lasting side effect in children View/ Open Date 2013-09 Format Metadata Abstract Before prescribing inhaled corticosteroids (...) (ICS) for a child with asthma, tell the patient -- and parents -- that their use could lead to a small but permanent effect on adult height. Stength of recommendation: B: Based on one prospective study. URI Part of Citation Journal of Family Practice, 62(9) 2013: 500-502. Rights OpenAccess. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License. Collections hosted by hosted by

2014 PURLS

91. Statins have no side effects? What our study really found, its fixable flaws, and why trials transparency matters (again).

Statins have no side effects? What our study really found, its fixable flaws, and why trials transparency matters (again). Statins have no side effects? What our study really found, its fixable flaws, and why trials transparency matters (again). – Bad Science Search TED Talk Collected Journalism This Nerdy Book This Great Book T-shirts Categories (3) (4) (6) (45) (28) (6) (16) (190) (5) (20) (52) (88) (2) (1) (2) (1) (677) (4) (14) (2) (37) (4) (9) (3) (11) (6) (3) (16) (13) (1) (6) (8) (6) (6 (...) ) (12) (1) (59) (2) (6) (34) (26) (1) (1) (1) (2) (2) (1) (52) (7) (2) (1) (2) (3) (1) (1) (1) (4) (2) (82) (1) (10) (6) (3) (2) (1) (5) (1) (10) (1) (2) (1) (1) (6) (4) (3) (2) (52) (3) (18) (10) (1) March 13th, 2014 by Ben Goldacre in , , | Hi there, sorry to be absent (dayjob!). I was surprised to see a study I’m a co-author on getting some today, under the headline “Statins ‘have no side effects'”. That’s not what found. But it was an interesting piece of work, with an odd result, looking

2014 Bad Science

92. Exercise training programs improve short- to long-term side effects on physical functioning, quality of life, and cancer-related fatigue among children with acute lymphoblastic leukemia

Exercise training programs improve short- to long-term side effects on physical functioning, quality of life, and cancer-related fatigue among children with acute lymphoblastic leukemia Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites (...) . Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures Timing and effect measures Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Context and rationale Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Example: Screening will be performed

2014 PROSPERO

93. Randomised controlled trial: Citalopram decreases agitation in the context of Alzheimer's disease, but at doses higher than those commonly prescribed and at the expense of side effects

Randomised controlled trial: Citalopram decreases agitation in the context of Alzheimer's disease, but at doses higher than those commonly prescribed and at the expense of side effects Citalopram decreases agitation in the context of Alzheimer's disease, but at doses higher than those commonly prescribed and at the expense of side effects | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via (...) of Alzheimer's disease, but at doses higher than those commonly prescribed and at the expense of side effects Article Text Therapeutics Randomised controlled trial Citalopram decreases agitation in the context of Alzheimer's disease, but at doses higher than those commonly prescribed and at the expense of side effects Benjamin R Underwood 1 , Chris Fox 2 Statistics from Altmetric.com Commentary on: Porsteinsson AP , Drye LT , Pollock BG , et al . Effect of citalopram on agitation in Alzheimer disease

2014 Evidence-Based Medicine

94. Paliperidone depot is not different from haloperidol in relapse prevention of schizophrenia, but different side effects should be considered

Paliperidone depot is not different from haloperidol in relapse prevention of schizophrenia, but different side effects should be considered Paliperidone depot is not different from haloperidol in relapse prevention of schizophrenia, but different side effects should be considered | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use (...) side effects should be considered Article Text Pharmacological interventions Paliperidone depot is not different from haloperidol in relapse prevention of schizophrenia, but different side effects should be considered Oliver Freudenreich Statistics from Altmetric.com What is already known on this topic? Reducing the occurrence of relapse in schizophrenia is an important treatment goal. Antipsychotics are effective in reducing relapse rates but they are often not taken regularly because of poor

2014 Evidence-Based Mental Health

95. A comparison of the cosmetic efficacy and side effects associated with three botulinum toxin A formulations: a systematic review and meta-analyses

A comparison of the cosmetic efficacy and side effects associated with three botulinum toxin A formulations: a systematic review and meta-analyses Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith (...) " or "Joanne") for correspondence: Organisation web address: Timing and effect measures Timing and effect measures Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Context and rationale Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Example: Screening will be performed in two phases, namely initial screening

2014 PROSPERO

96. Domperidone: risks of cardiac side effects

Domperidone: risks of cardiac side effects Domperidone: risks of cardiac side effects - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Domperidone: risks of cardiac side effects Indication restricted to nausea and vomiting, new contraindications, and reduced dose and duration of use. Published 11 December 2014 From: Therapeutic area: , Article date: May 2014 Domperidone is a dopamine antagonist with antiemetic properties. A European review assessed the benefits and risks (...) of domperidone following continued reports of cardiac side effects. The review confirmed a small increased risk of serious cardiac side effects. A higher risk was observed particularly in people older than 60 years, people taking daily oral domperidone doses of more than 30 mg, and those taking QT-prolonging medicines or CYP3A4 inhibitors at the same time as domperidone. For indications other than nausea and vomiting, the benefits were not considered to outweigh the cardiac risk. Based on the results

2014 MHRA Drug Safety Update

97. Ivabradine (Procoralan) in the symptomatic treatment of angina: risk of cardiac side effects

Ivabradine (Procoralan) in the symptomatic treatment of angina: risk of cardiac side effects Ivabradine (Procoralan) in the symptomatic treatment of angina: risk of cardiac side effects - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Ivabradine (Procoralan) in the symptomatic treatment of angina: risk of cardiac side effects New advice to minimise risk Published 19 December 2014 From: Therapeutic area: Ivabradine (Procoralan) is used to treat chronic heart failure

2014 MHRA Drug Safety Update

98. Meta-analysis of side effects of statins shows need for trial transparency. Full Text available with Trip Pro

Meta-analysis of side effects of statins shows need for trial transparency. 24780760 2014 06 02 2018 10 23 1756-1833 348 2014 Apr 29 BMJ (Clinical research ed.) BMJ Meta-analysis of side effects of statins shows need for trial transparency. g2940 10.1136/bmj.g2940 bmj.g2940 Goldacre Ben B London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK. eng Letter 2014 04 29 England BMJ 8900488 0959-8138 0 Hydroxymethylglutaryl-CoA Reductase Inhibitors AIM IM Clinical Trials as Topic (...) standards Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors adverse effects Meta-Analysis as Topic Periodicals as Topic standards Publishing standards Research Report standards 2014 5 1 6 0 2014 5 2 6 0 2014 6 3 6 0 epublish 24780760 10.1136/bmj.g2940

2014 BMJ

99. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. (Abstract)

Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Methotrexate (MTX) is a disease modifying antirheumatic drug (DMARD) used as a first line agent for treating rheumatoid arthritis (RA). Pharmacologically, it is classified as an antimetabolite due to its antagonistic effect on folic acid metabolism. Many patients treated with MTX experience mucosal, gastrointestinal, hepatic or haematologic side effects. Supplementation with folic (...) or folinic acid during treatment with MTX may ameliorate these side effects.To identify trials of supplementation with folic acid or folinic acid during MTX therapy for rheumatoid arthritis and to assess the benefits and harms of folic acid and folinic acid (a) in reducing the mucosal, gastrointestinal (GI), hepatic and haematologic side effects of MTX, and (b) whether or not folic or folinic acid supplementation has any effect on MTX benefit.We originally performed MEDLINE searches, from January 1966

2013 Cochrane

100. Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of head-head comparisons

Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of head-head comparisons Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2013 DARE.